Table 2.

Outcomes of ruptured and unruptured dominant follicles during the five days following randomization to the etonorgestrel implant with or without ulipristal acetate 30mg oral stratified by follicle size on day of randomization.

	Implant Only (n=20)			Implant + UPA (n=19)
	<15mm	≥15mm	All	<15mm	≥15mm	All
Follicular rupture			8			12
Ovulation1	2	5	7	4	8	12
Ovulation dysfunction2	1		1			0
No Follicular Rupture			12			7
Follicular atresia3	1		1	1		1
Persistently enlarged follicle4	7	2	9	1	5	6
Luteinized unruptured follicle5	1	1	2			0
			35% ovulation			63% ovulation

¹Ovulation= a follicle ≥15mm that disappears or decreases in size by >50% and serum progesterone >3 ng/mL. It MAY be preceded 24–48 h by an LH surge (≥21 IU/L)

²Ovulation dysfunction= a follicle ≥15mm that disappears or decreases in size by >50% but not proceeded by an LH surge or preceded by a blunted (<21 IU/L) LH surge and without any progesterone >3 ng/mL

³Follicular atresia = a follicle <15 mm with arrest in growth or decrease in size of <50% without any progesterone >3 ng/mL

⁴Persistently enlarged follicle = a follicle measuring ≥15 mm that persists for at least one week without any progesterone >3 ng/mL

⁵Luteinized unruptured follicle= a follicle ≥15 mm that persists for at least one week with at least one progesterone >3 ng/mL